Date | Price Target | Rating | Analyst |
---|---|---|---|
8/8/2024 | $13.00 → $11.00 | Outperform | Oppenheimer |
5/31/2024 | $11.00 | Overweight | Piper Sandler |
1/5/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
1/5/2024 | Buy → Neutral | Guggenheim | |
12/8/2023 | $7.00 | Buy | Citigroup |
12/8/2023 | Buy | Citigroup | |
6/26/2023 | $28.00 | Outperform | Oppenheimer |
3/21/2023 | $6.00 | Mkt Perform | Bernstein |
Oppenheimer resumed coverage of Allogene with a rating of Outperform and set a new price target of $11.00 from $13.00 previously
Piper Sandler initiated coverage of Allogene with a rating of Overweight and set a new price target of $11.00
JMP Securities downgraded Allogene from Mkt Outperform to Mkt Perform
A revolutionary cell-based gene therapy is showing promise for treating autoimmune diseases. Professor Georg Schett, a rheumatologist at University Hospital Erlangen in eastern Germany, used chimeric antigen receptor (CAR-T) cell therapy, typically used for blood cancers, for autoimmune conditions like lupus, when the immune system attacks healthy cells and tissues by mistake. This attack causes inflammation. The Financial Times writes that the early success of CAT-T therapy has reignited discussions about its potential beyond blood cancers, though challenges remain. Professor Georg Schett noted that this approach could revolutionize autoimmune disease treatment, providing a one-tim
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer InstituteALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (1L) Treatment at Community Cancer Centers, Where 80% of Patients Receive CareALPHA3 Expected to Complete Enrollment in 1H 2026; Potential BLA Submission in 2027
ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure Rates First Prospective Trial to Incorporate the Foresight Diagnostics's Investigational CLARITY™ Test to Identify Patients with LBCL Who Have Minimal Residual Disease (MRD) and are Likely to Relapse Following Standard 1L TreatmentUnique Profile of Investigational AlloCAR T™ Products May Expand Access to CAR T within Community Cancer Centers where Most 1L Patients are ManagedALPHA3 Expected to Complete Enrollment in 1H 2026; BLA Submission Anticipated in 2027
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
3 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in panel focused on innovations in the allogeneic cell therapy landscape during the Goldman Sachs Cell Therapy Day on October 1, 2024 in New York. Goldman Sachs Cell Therapy DayTuesday, October 1, 2024Panel Discussion: 10:00AM PT/1:00PM ET A webcast of this panel discussion will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a li
The CD19/CD70 Dual CAR is Specifically Designed to Address Both the B-cell and T-cell Dysfunction Implicated in Autoimmune DiseasesALLO-329, is an Investigational Product Built on a New Gene Editing Platform that Features Site-Specific Integration, Intended to Reduce the Risk of Secondary Malignancies, and Leverage the Clinically Validated Dagger® Effect Aimed at Reducing or Eliminating Lymphodepletion, a Potential Barrier in the Adoption of CAR T in Autoimmune Indications SOUTH SAN FRANCISCO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in August and September. Canaccord Genuity 44th Annual Growth Conference Tuesday, August 13, 20247:00AM PT/10:00AM ET Baird 2024 Global Healthcare Conference Wednesday, September 11, 20247:15AM PT/10:15AM ET Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webc
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)
SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)
SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer. Mr. Parker will oversee the Company's financial operations and business strategy and will serve as a member of the Leadership Team. "Geoff's extensive experience in biotechnology across all aspects of finance and business development strategy will be of tremendous value to Allogene as we advance our critical pipeline assets and explore new opportunities," said David Chang, M.D., Ph.D.
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that Earl Douglas has been appointed as General Counsel. Mr. Douglas will oversee all aspects of the Company's legal function and serve as a member of the Leadership Team. "We are excited to welcome Earl who brings a tenure of experience guiding publicly-traded biotech companies on complex legal issues, corporate strategy and transactions," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "I also want to th
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipelineFormer Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and deliver
144 - Allogene Therapeutics, Inc. (0001737287) (Subject)
10-Q - Allogene Therapeutics, Inc. (0001737287) (Filer)
8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)
Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation in Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Initiated in June 2024Patient Screening for Minimal Residual Disease (MRD) and Enrollment Proceeding as Planned with Ten Community and Academic Sites Opened to Date Across the USEnrollment Completion Expected in 1H 2026 and Potential BLA Submission in 2027 ALLO-329 in Autoimmune Disease (AID) Investigational New Drug (IND) Application for Next-Generation CD19/CD70 Dual CAR with Dagger® Technology Designed for AID on Track for Q1 2025 with Proof-of-Concept Data Expected by YE 2025 ALLO-316 in Renal Cell Carcinoma (RCC) Phase 1 TRAVERSE Data Update Including Details on the Diag
Conference Call and Webcast Scheduled for August 7, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report second quarter 2024 financial results and provide a business update on August 7, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. Listen-Only WebcastThe listen-only webcast will be made available on the Company's website at www.a
Cemacabtagene Ansegedleucel (Cema-Cel) Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforcing Company's Conviction in the Unique Opportunity in Large B Cell Lymphoma (LBCL) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Extended Territory Rights Substantially Increase Market Opportunity in 1L Consolidation LBCL and R/R CLL From More Than $6 Billion in the US to More Than $9.5 Billion in the Combined U.S., EU Member States and the United KingdomConsolidated Rights Provide Greater Flexibility for Future Cema-Cel Partnerships to Expand Commercial Footprint Pivotal Phase 2 ALPHA3 1L Consolidation LBCL Trial Expected to Begin Mid-2024In